Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fentanyl sublingual - BTcP Pharma/Pharmbio Korea

Drug Profile

Fentanyl sublingual - BTcP Pharma/Pharmbio Korea

Alternative Names: Fentanyl SL spray - INSYS Therapeutics; Fentanyl sublingual spray - INSYS Therapeutics; FSS; Subsys

Latest Information Update: 31 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Developer INSYS Therapeutics, Inc; M. D. Anderson Cancer Center
  • Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain
  • Discontinued Dyspnoea; Postoperative pain

Most Recent Events

  • 27 Jan 2021 M.D. Anderson Cancer Center and INSYS Therapeutics completes a phase II/III trial in Dyspnoea in USA (Sublingual) (NCT02597478)
  • 07 Aug 2020 M.D. Anderson Cancer Center and INSYS Therapeutics terminates phase II trial in Cancer pain in USA (Sublingual) (NCT02514252)
  • 08 May 2018 Lunatus acquires licence for Fentanyl sublingual formulation from INSYS Therapeutics in Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top